$13.46
-0.09 (-0.66%)
ISIS Pharmaceuticals, Inc. (ISIS)
CAPS Rating:
The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.
RSS Headlines
Fool UK
Recs
Mixed emotions on this one since all Income relies on license agreements, contracts, government grants (i.e., prefer cash and consumer staples at such times). Possibly a bad call if we truly enter a recession - regardless of how much "...is in the pipe line". Not for the faint of heart. I sold out myself. In the near term, stock will trade in an active range and likely end up higher. If times get tough, however, this could rapidly change (for the worse). Still, if the economy improves, could be a great value.